IL324086A - Production method - Google Patents

Production method

Info

Publication number
IL324086A
IL324086A IL324086A IL32408625A IL324086A IL 324086 A IL324086 A IL 324086A IL 324086 A IL324086 A IL 324086A IL 32408625 A IL32408625 A IL 32408625A IL 324086 A IL324086 A IL 324086A
Authority
IL
Israel
Prior art keywords
drug product
packaged
radiopharmaceutical drug
radiopharmaceutical
producing
Prior art date
Application number
IL324086A
Other languages
Hebrew (he)
Inventor
Geert Vandenbossche
Original Assignee
Novartis Ag
Geert Vandenbossche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Geert Vandenbossche filed Critical Novartis Ag
Publication of IL324086A publication Critical patent/IL324086A/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/003—Filling medical containers such as ampoules, vials, syringes or the like
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B57/00—Automatic control, checking, warning, or safety devices
    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
    • G21G4/00—Radioactive sources
    • G21G4/04—Radioactive sources other than neutron sources
    • G21G4/06—Radioactive sources other than neutron sources characterised by constructional features
    • G21G4/08—Radioactive sources other than neutron sources characterised by constructional features specially adapted for medical application
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B2220/00—Specific aspects of the packaging operation
    • B65B2220/16—Packaging contents into primary and secondary packaging

Landscapes

  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Filling Of Jars Or Cans And Processes For Cleaning And Sealing Jars (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)

Description

. 1 . PAT059492 FF METHOD OF PRODUCTION Description FIELD OF THE INVENTION The present disclosure relates to a method of producing a packaged radiopharmaceutical drug product by operating the different manufacturing steps including inspection in various cold and shielded units of cleanliness zoning requirements of Grade A, B, C, or CNC. It further relates to the manufacturing units comprising technical equipment for said method, the drug product obtained by said method, as well as its technical and medical use.
BACKGROUND OF THE INVENTION The manufacturing of radiopharmaceutical drug products is challenging. Those products are typically administered parenterally and therefore require aspetic manufacturing in a strict quality controlled environment to ensure sterility of the final product.
Due to the radioactivity of said products the manufacturing is to be done in shielded units. The current practice is to perform the entire production of a radiopharmaceutical product in a single shielded isolator that allows manipulations via gloves or gripping devices from outside the isolator and material locks for educt and product transfers into and out of said isolator. Said isolator has to meet cleanliness zoning requirement Grade A for an aseptic production of a sterile radiopharmaceutical product.
Every process material that is or was inside said box is potentially contaminated by radioactivity and thus require particular waste management.
Further, the quality controls and inspection of the final radiopharmaceutical product is also challenging. A container closure integrity test has to be done but bears the risk to contaminate the entire production unit in case of a identified leakage. Also, the visual inspection for particulate matter by naked eye of the operator from a short distance is difficult due to the radioactivity of the product which can only be visually monitored through thick lead glasses of imperfect transparency. -2-PATO59492 FF During the past years, several new radiopharmaceutical drug products have been demonstrated by pivotal clinical trials to be a safe and effective cancer treatment option (e.g. LUTATHERA and PLUVICTO). With the approvals of those drugs and the their broader clinical use, the demand for such radiopharmaceutical products has significantly increased and require production on large scale. Therefore, there is a high need for a more economic production on industrial scale.
SUMMARY OF THE INVENTION The present disclosure provides such a highly economic production method on an unprecedented industrial scale and is suitable for implementation as automated process line. It reduces significantly radioactive contaminated waste and de-risks radioactive contamination of the process line during the manufacturing process and product quality control steps and provides highly efficient and reliable product inspection solutions. It further provides a primary and secondary packaging solutions that are novel for radiopharmaceutical products.
The present disclosure provides said production method in the following aspects: A method for producing a packaged radiopharmaceutical drug product (e.g. a radioligand drug product) comprising the steps of:(1) Synthesizing and compounding a radiopharmaceutical drug substance solution in one or more shielded units of (cleanliness zoning requirement) Grade C to obtain a radiopharmaceutical drug product;(2) Providing primary packaging materials, e.g. by (outer-layer-)unpacking in one or more cold units of Grade C, sanetizing in one or more cold units of Grade B, and (inner-layer-)unpacking said packaging materials in one or more cold units of Grade A;(3) Filling the radiopharmaceutical drug substance solution obtained by step (1) into the primary packaging materials as provided and unpacked by step (2) in a shielded unit of Grade A to obtain the primarily packaged radiopharmaceutical drug product;(4) Inspecting the primarily packaged radiopharmaceutical drug product obtained by step (3) in one or more shielded units of Grade "Controlled, non-classified" (CNC); and(5) optionally, placing the primarily packaged radiopharmaceutical drug product as inspected by step (4) into a shielded secondary packaging material in one or more -3-PATO59492 FF shielded units of Grade CNC to obtained a primarily and secondarily packaged radiopharmaceutical drug product.
As described above, to prevent radio-active waste, all packaging components are unpakked in a cold area before entering in the filling unit. This prevents contamination risk. All tubs and bags can therefore be treated as non-radioactive and destroyed in a cheaper way.
The method for producing a packaged radiopharmaceutical drug product as described above, wherein in step (4) a container closure integrity test (CCIT) of the primarily packaged radiopharmaceutical drug product is performed as one of the first inspecting steps, preferably, the CCIT is performed with the primarily packaged radiopharmaceutical drug product present in a(n additional) container that allows capturing/segregation of the drug product in said container in case of any leakage detection or risk of spillage.
As a unique feature, the CCIT (container closure integrity testing) is done as a first step after filling. In this way,a) the vial is kept in a container to collect any liquid spilled;b) the vial is tested on integrity;c) in case of leakage, the cup and vial are seggregated and do not contaminate the line This setup serves 2 goals:Beside of ensuring that the container is integer (avoiding contamination risk for user and patient), this also ensures that a leaking container would not contaminate the production line.
The method for producing a packaged radiopharmaceutical drug product as described above, wherein in step (4) a camera assisted visual inspection (VI) is performed in the form of video recordation, preferably, said video recordation is then evaluated by naked-eye.
Visual inspection is typically done either:a) by naked eye looking at the vial, but this is not possible for radiopharmaceutical products because of the radioactivity and low resolution behind leaded glass; orb) by a camera and image analysis system is used to detect particles automatically (image analysis) -4-PATO59492 FF The novel approach of the present disclosure is to record a video and evaluate said recording with the naked eye.
The method for producing a packaged radiopharmaceutical drug product as described above, wherein in step (1) the synthesizing step is performed several times, preferable up to times, preferably said synthesizing step is performed in parallel in several synthesizing units, and the resulting synthesized radiopharmaceutical drug substance solutions are then collected as one combined (bulk) volume for compounding.
The method for producing a packaged radiopharmaceutical drug product as described above, wherein the primary packaging material comprises a glass vial and an all-plastic push-fit cap, wherein the rubber stopper is pre-assembled in the cap, for example, a RayDyLyo cap by ARaymond.
The method for producing a packaged radiopharmaceutical drug product as described above, wherein the shielded secondary packaging material comprises a lead pot with a corresponding lid, preferably with a tamper evident application, preferably said lead pot and its lid is free of a paint-coating, preferably said lead pot and its lid are plastic-coated, preferably a rubber ring is present between pot and lid for leakage-safe closure.
The method for producing a packaged radiopharmaceutical drug product as described above, wherein the drug substance carrying containers and tubings connecting said containers are flushed with protective gas / inert gas, for example nitrogen (N2) and/or argon (Ar).
The method for producing a packaged radiopharmaceutical drug product as described above, wherein the solutions involved in the method are transferred from one container to the other via tubings by applying overpressure of protective gas / inert gas, for example nitrogen (N2) and/or argon (Ar), preferably, said transfer is preceded by testing the tubings for flow and leakage, e.g. by a pressure test with said protective gas / inert gas.
The method for producing a packaged radiopharmaceutical drug product as described above, wherein said product is produced on a scale of at least 30 Ci, preferably at least 32 Ci, more preferably 35 Ci, even more preferably at least 40 Ci.
BRIEF DESCRIPTION OF THE DRAWINGS -5-PATO59492 FF Figure 1 shows a top view of a linearly arranged example production line (with two synthesis units and two compounding untis). Shielded unit for beta (optional alpha)/gamma irradiation; Thin line: Cold unit; Dash line: Optional.
Figure 2 shows a schematic overview of the modules of an example production line (with synthesis units and one compounding unit). Thick line: Shielded unit for beta (optional alpha)/gamma irradiation; Thin line: Cold unit; Dash line: Optional. "BC" indicates the Grade A Filling unit outlet of first Grade B and then Grade C.
DETAILED DESCRIPTION OF THE INVENTION Herein after, the present disclosure is described in further detail and is exemplified.
EmbodimentsThe methods of treatments of the present disclosure are provided in particular as following embodiments: 1. A method for producing a packaged radiopharmaceutical drug product (e.g. a radioliganddrug product) comprising the steps of:(1) Synthesizing and compounding a radiopharmaceutical drug substance solution in one or more shielded units of (cleanliness zoning requirement) Grade C to obtain a radiopharmaceutical drug product;(2) Providing primary packaging materials (e.g. as ready-to-use materials, in sealed tubs), e.g. by (outer-layer-)unpacking in one or more cold units of Grade C, sanetizing in one or more cold units of Grade B, and (inner-layer-)unpacking (e.g. removing the Tyvek sheet from the tub) said packaging materials in one or more cold units of Grade A;(3) Filling the radiopharmaceutical drug substance solution obtained by step (1) into the primary packaging materials as provided and unpacked by step (2) in a shielded unit of Grade A to obtain the primarily packaged radiopharmaceutical drug product;(4) Inspecting the primarily packaged radiopharmaceutical drug product obtained by step (3) in one or more shielded units of Grade "Controlled, non-classified" (CNC); and -6-PATO59492 FF (5) optionally, placing the primarily packaged radiopharmaceutical drug product as inspected by step (4) into a shielded secondary packaging material in one or more shielded units of Grade CNC to obtained a primarily and secondarily packaged radiopharmaceutical drug product.
In certain embodiments, the unpacking and sanetization in step (2) is done in the following way:In a cold unit of Grade C, the outer bags surrounding a sealed tubs are removed.In a cold unit of Grade B, sanetization of the sealed tubs is done.In a cold unit of Grade A, unsealing of the tubs is done, e.g. by removing the Tyvek sheet from the tub.
In certain embodiments, the units are linearly arranged, e.g. as shown in Figure 1. The linearly arranged units are considered as preferred option. 2. The method for producing a packaged radiopharmaceutical drug product according to embodiment 1, wherein in step (4) a container closure integrity test (CCIT) of the primarily packaged radiopharmaceutical drug product is performed as one of the first inspecting steps, preferably, the CCIT is performed with the primarily packaged radiopharmaceutical drug product present in a(n additional) container that allows capturing/segregation of the drug product in said container in case of any leakage detection or risk of spillage. 3. The method for producing a packaged radiopharmaceutical drug product according to embodiment 1 or 2, wherein in step (4) a camera assisted visual inspection (VI) is performed in the form of video recordation, preferably, said video recordation is then evaluated by naked-eye. 4. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding embodiments, wherein in step (1) the synthesizing step is performed several times, preferable up to 4 times, preferably said synthesizing step is performed in parallel in several synthesizing units, and the resulting synthesized radiopharmaceutical drug substance solutions are then collected as one combined (bulk) volume for compounding. -7-PATO59492 FF . The method for producing a packaged radiopharmaceutical drug product according any one of the preceding embodiments, wherein in step (1) the synthesizing step is performed in a cassette-based synthesis units, preferably said cassette-system manufacturing synthesizer unit as provided e.g. by Trasis, preferably MiniAIO as described e.g. in WO 2020/089379 A1, preferably, two double synthesis units by Trasis are used. 6. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding embodiments, wherein in step (1) the compounding step comprises the sub-steps of:(i) Filling the synthesized solution(s) into a container, e.g. a (bulk) vial or bottle to obtain a (concentrated) mother solution;(ii) optionally, measuring the radioactivity of said (concentrated) mother solution;(iii) optionally, transferring said (concentrated) mother solution into another contrainer, preferably a flexible plastic bag,(iv) adding a dilution solution in an amount to obtain the drug substance solution in the desired radioactive concentration; and(v) mixing the solution as result of step (iv), preferably and if applicable, by moving the flexible plastic bag appropriately, to obtain a homogeneous diluted drug substance solution for filling. 7. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding embodiments, wherein in step (2) the packaged primary packaging material is (bio)decontaminated/sanitized, preferably with vaporized hydrogen peroxide (VHP), before being transferred from the unit of Grade B to the unit of Grade A. 8. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding embodiments, wherein in step (4) inspecting comprises the following sub-steps:(i) CCIT;(ii) radioactive dose measurement/calibration;(iii) visual inspection; and(iv) optionally, head space analysis;preferably in said order. -8-PATO59492 FF 9. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding embodiments, wherein the primary packaging material comprises a glass vial and an all-plastic push-fit cap, wherein the rubber stopper is pre-assembled in the cap, for example, a RayDyLyo cap by ARaymond.
. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding embodiments, wherein the shielded secondary packaging material comprises a lead pot with a corresponding lid, preferably with a tamper evident application, preferably said lead pot and its lid is free of a paint-coating, preferably said lead pot and its lid are plastic-coated, preferably a rubber ring is present between pot and lid for leakage-safe closure. 11. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding embodiments, wherein the drug substance carrying containers and tubings connecting said containers are flushed with protective gas / inert gas, for example nitrogen (N2) and/or argon (Ar). 12. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding embodiments, wherein the solutions involved in the method are transferred from one container to the other via tubings by applying overpressure of protective gas / inert gas, for example nitrogen (N2) and/or argon (Ar), preferably, said transfer is preceded by testing the tubings for flow and leakage, e.g. by a pressure test with said protective gas / inert gas. 13. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding embodiments, wherein the solutions used in the method are purged and/or flushed with protective gas / inert gas, for example nitrogen (N2) and/or argon (Ar). 14. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding embodiments, wherein the at least the steps (1) - (3) are automated, preferably also the steps (4) and (5) are automated, with the exception of the naked-eye evaluation of the video recordation in step (4).
. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding embodiments, wherein said product is produced on a scale of at -9-PATO59492 FF least 30 Ci, preferably at least 32 Ci, more preferably 35 Ci, even more preferably at least 40 Ci. 16. A packaged radiopharmaceutical drug product obtained (and/or obtainable) by the methods as described in anyone of the preceding embodiments. 17. A manufacturing unit (e.g. in the form of a(n automated) process line) comprising the technical equipment and facilities for produdig a packaged radiopharmaceutical drug product according to the methods as described in anyone of the preceding embodiments. 18. Use of the manufacturing unit according to embodiment 17 for producing the packaged radiopharmaceutical drug product. 19. A method of treating a cancer comprising administering to a patient in need thereof a therapeutically effective amount of the radiopharmaceutical drug product contained in the packaged radiopharmaceutical drug product according to embodiment 16.
. The radiopharmaceutical drug product contained in the packaged radiopharmaceutical drug product according to embodiment 16 for use in the treatment of a cancer. 21. Use of the radiopharmaceutical drug product contained in the packaged radiopharmaceutical drug product according to embodiment 16 for the preparation of a medicament for the treatment of a cancer.
DEFINITIONS (and further embodiments and embodiment feature descriptions) "about" in respect of a value means ± 25%, preferably ± 20%, more preferably ± 15%, even more preferably ± 10%, even more preferably ± 5%.
Radiopharmaceutical drug product:In certain embodiments of the present disclosure, the term radiopharmaceutical drug product may refer to any drug product that comprises a radioactive material, e.g. a radioactive nuclide, - 10-PATO59492 FF radionuclide or radioisotope, e.g. F-18, Cu-64, Cu-67, Ga-68, Y-90, Tc-99m, 1-131, Tb-161, Er- 169, Lu-177, Pb-212, Bi-212, Ra-223, Ac-225. The radionuclide may be present in such drug product in the form of a salt, e.g. as aqueous solution (e.g. Radium chloride solution, Xofigo), or covalently bound to an organic molecule, e.g. 18F-DCFPyL, Pylarify), or complexed in a chelator, whereby said chelator might be conjugated (e.g. via a linker) to a target-binding moiety, i.e. a radioligand, e.g. 177Lu-DOTATATE, Lutathera, or 177Lu-PSMA-617, Pluvicto.
Radioligand drug product:In certain embodiments of the present disclosure, the term radioligand drug product may refer to a drug product comprising a radioligand for therapeutic use (i.e. a radioligand therapeutic (RLT) agent or for imaging use (i.e. a radio ligand imaging (RLI) agent).
The RLT agent may comprise at least two components:(1) a radionuclide component; and(2) a ligand component;wherein said radionuclide component (1) comprises:(a) at least one radionuclide, preferably selected from the group consisting of alpha particle-emitting radionuclide, beta-minus electron-emitting radionuclide and Auger electron-emitting radionuclide, more preferably a beta-minus electron- emitting radionuclide ; andwherein said ligand component (2) comprises:(b) at least one target binding moiety (e.g. a PSMA-binding moiety, or an somatostatin receptor targeting moiety);(c) optionally at least one chelator for chelating the radionuclide or a salt comprising the radionuclide, or a prosthetic group residue from a radiohalogenation reaction;(d) optionally at least one linker connecting the PSMA-binding moiety (b) with the chelator or prosthetic group component (c), preferably said linker is a chemical moiety or a covalent bond;(e) optionally at least one additional moiety that alters the systemic circulation time, tumor uptake, and/or biodistribution of the RLT agent, preferably said altering moiety comprises oxyethylene units, e.g. an oligo- or polyoxyethylene -(-CH2-CH2- O-)n- with n = 2 - 100, or is an albumin-binding moiety (e.g. Evans blue, 4-(p- iodophenyl)butyric acid, 4-(p-methylphenyl)butyric acid, ibuprofen). - 11 -PATO59492 FF The radionuclide may be selected from the group consisting of Lu-177, Tb-161,1-131, Tc-99m, Y-90, Sc-47, Cu-67, Re-188, Pb-212, Bi-213, Ac-255, and Th-227, preferably selected from the group consisting of Lu-177 and Tb-161.
The radionuclide may be a beta-minus electron emitting radionuclide with an half-life of from about 2 to about 10 days, preferably from about 5 to about 10 days, more preferably from about to about 8 days , even more preferably about 6 or about 7 days; and a beta-minus electron maximum energy of from about 0.3 to about 1.0 MeV, preferably from about 0.5 to about 0.MeV, more preferably about 0.5, 0.6, 0.7 or 0.8 MeV, even more preferably about 0.5 or about 0.6 MeV.
The radionuclide may be a beta-minus electron emitting radionuclide with an absorbed electron energy fraction per decay of from 100 to 300 keV/decay, from 120 to 250 keV/decay, from about 150 keV/decay (e.g. for Lu-177: 147 keV) to about 200 keV/decay (e.g. for Tb-161: 1keV/decay).
The ligand may be selected from the group consisting of PSMA-617, PSMA l&T, PSMA-R2, MIP-1095, MIP-1545, MIP-1555, MIP-1557, MIP-1558, CTT1403, FC705, BAY-2315497, TLX592, PSMA-TCC, rhPSMA, rhPSMA-7, rhPSMA-7.3, rhPSMA-10.1, Ludotadipep, PNT2001, PNT2002, PSMA-7 l&T, EB-PSMA-617, PSMA-ALB-02, PSMA-ALB-053, PSMA- ALB-056, P16-093, PSMA-93, and RPS-074 (or any albumin-binder-modified versions thereof, e.g. Evans blue (EB)-PSMA-617), preferably selected from the groupd consisting of PSMA- 617, PSMA l&T, and PSMA-R2.
The PSMA-binding moiety may comprise at least two amino acids connected via an urea or phosphoramide group, preferably glutamate-urea-lysine (GUL), or an antibody or fragment thereof, e.g. TLX591, J591, rosopatamab, IAB2M, GCP-05, 1H8H5, SP29, or FOLHI.
The radioligand therapeutic agent may be selected from the group consisting of [177Lu]Lu- PSMA-617 (lutetium (177Lu) vipivotide tetraxetan), [177Lu]Lu-EB-PSMA-617 (Evans Blue modified [177Lu]Lu-PSMA-617), and [177Lu]Lu-PSMA l&T (lutetium (177Lu) zadavotide guraxetan), [161Tb]Tb-PSMA-617 (terbium (161Tb) vipivotide tetraxetan), [161Tb]Tb-EB- PSMA-617 (Evans Blue modified [161Tb]Tb-PSMA-617), and [161Tb]Tb-PSMA l&T (terbium (161Tb) zadavotide guraxetan), preferably [177Lu]Lu-PSMA-617 (lutetium (177Lu) vipivotide - 12 -PATO59492 FF tetraxetan) or [161Tb]Tb-PSMA-617 (terbium (161Tb) vipivotide tetraxetan), more preferably [177Lu]Lu-PSMA-617 (lutetium (177Lu) vipivotide tetraxetan).
The PSMA-binding moiety may be glutamate-urea-lysine (GUL) and the linker may comprise the residues of (2-naphthyl)-L-alanine and trans-4-aminomethyl-cyclohexanecarboxylic acid or the linker comprises the residues of an optionally substituted phenyl-alanine and/or optionally substituted tyrosine, preferably, a phenyl-alanine and a subtstituted tyrosine, more preferably a phenyl-alanine and a iodo-substituted tyrosine, even more preferably a D-phenyl-alanine and a iodo-substituted D-tyrosine.
The ligand may be selected from the group consisting of DOTA-OC: [DOTAO.D- Phe1 ]octreotide, DOTA-TOC: [DOTAO,D-Phe1,Tyr3]octreotide, edotreotide (INN), DOTA- NOC: [DOTA0, D-Phe1,1-Nal3]octreotide, DOTA-TATE: [DOTAO,D-Phe1,Tyr3]octreotate, DOTA-Tyr3-Octreotate, DOTA-d-Phe-Cys-Tyr-d-Trp-Lys-Thr-Cys-Thr (cyclo 2,7), oxodotreotide (INN), DOTA-LAN: [DOTAO,D־p־Nal1]lanreotide, DOTA-VAP: [DOTAO.D- Phe1,Tyr3]vapreotide, Satoreotide trizoxetan, and Satoreotide tetraxetan.
The radioligand imaging agent may comprise:(1) a radionuclide component; and(2) a ligand component;wherein said radionuclide component (1) comprises:(a) at least one positron-emitting radionuclide; andwherein said ligand component (2) comprises:(b) at least one target-binding moiety (e.g. a PSMA-binding moiety, or an somatostatin receptor binding peptide, e.g. oxodotreotide or edotreotide);(c) optionally at least one chelator for chelating the radionuclide or a salt comprising the radionuclide, or a prosthetic group residue from a radiohalogenation reaction;(d) optionally at least one linker connecting the PSMA binding moiety (b) with the chelator/prosthetic group component (c), preferably said linker is a chemical moiety or a covalent bond.
The radionuclide for the RLI agent may be selected from the group consisting of F-18, Ga-67, Ga-68, and Cu-64. - 13-PATO59492 FF The ligand for the RLI agent may be selected from the group consisting of PSMA-(gozetotide), DCPyL (if labeled with 18F available as PYLARIFY, INN: piflufolastat F-18, also referred to shortly as PyL), MIP-1404, rhPSMA 07, PSMA-1007, THP-PSMA, iPSMA, P16- 093, PSMA-93, rhPSMA, rhPSMA-7, rhPSMA-7.3, PSMA-7, and PSMA I&T.
The ligand may be selected from the group consisting of DOTA-OC: [DOTAO,D- Phe1 ]octreotide, DOTA-TOC: [DOTAO,D-Phe1,Tyr3]octreotide, edotreotide (INN), DOTA- NOC: [DOTA0, D-Phe1,1-Nal3]octreotide, DOTA-TATE: [DOTAO,D-Phe1,Tyr3]octreotate, DOTA-Tyr3-Octreotate, DOTA-d-Phe-Cys-Tyr-d-Trp-Lys-Thr-Cys-Thr (cyclo 2,7), oxodotreotide (INN), DOTA-LAN: [DOTA0,D־p־Nal1]lanreotide, DOTA-VAP: [DOTAO.D- Phe1,Tyr3]vapreotide, Satoreotide trizoxetan, and Satoreotide tetraxetan.
Synthesizing (Step 1):In certain embodiments of the present disclosure, the term "synthesizing" may refer to radiolabeling a target-binding ligand, e.g. by complexing a radiometal into the chelator of the ligand. Said radiolabeling may require heating a solution of the radionuclide and the ligand for a certain time (e.g. about 5-15 min) and at a certain temperature (e.g. about 95°C). The solution may contain a buffer for ensuring the pH is optimal for the complex formation (e.g. e.g. an acetate buffer for a pH of about 4-6), a stabilizer against radiolytic degradation (autoradiolysis), e.g. gentisic acid or ascorbic acid, or salts thereof. The result of this radiolabling may be referred to as mother solution or concentrated mother solution.The synthesizing step may be performed in a cassette-based synthesis units, preferably said cassette-system manufacturing synthesizer unit as provided e.g. by Trasis, preferably MiniAIO as described e.g. in WO 2020/089379 A1 (the content of it are incorporated by reference), preferably, two double synthesis units by Trasis are used.
Compounding (Step 1):In certain embodiments of the present disclosure, the term "compounding" may refer to diluting the concentrated mother solution, e.g. by adding water or an aqueous solution optionally comprising a sequestering agent (e.g. DTPA), a stabilizer against radiolytic degradation (autoradiolysis), e.g. gentisic acid or ascorbic acids, or salts thereof, optionally also a isotonic agent, e.g. NaCI, to adjust the tonicity of the resulting solution, and optionally a pH adjusting agent, e.g. NaOH or HCI to adjust the pH to bring the pH closer to physiological pH. The aim of this dilution step is to adjust the radioactivity concentration to a target concentration that - 14-PATO59492 FF then suitable for the filling step to produce the patient dose units, e.g. about 1000 MBq/mL (mCi/mL).The compounding step may comprise the sub-steps of:(i) Filling the synthesized solution(s) into a container, e.g. a (bulk) vial or bottle to obtain a (concentrated) mother solution;(ii) optionally, measuring the radioactivity of said (concentrated) mother solution;(iii) optionally, transferring said (concentrated) mother solution into another contrainer, preferably a flexible plastic bag,(iv) adding a dilution solution in an amount to obtain the drug substance solution in the desired radioactive concentration; and(v) mixing the solution as result of step (iv), preferably and if applicable, by moving the flexible plastic bag appropriately, to obtain a homogeneous diluted drug substance solution for filling.
Shielded unit:In certain embodiments of the present disclosure, the term "shielded unit" may refer to a manufacturing unit that is shielded by a material suitable to prevent that ionizing radiation (e.g. alpha-particle, beta-minus electrons, gamma-rays) is leaving said unit. Therefore, within said shielded units radioactive material can be safely handled.
Cold unit:In certain embodiments of the present disclosure, the term "cold unit" may refer to those manufacturing units that are not shielded against ionizing radiation. Therefore, in those cold units, no radioactive material should be handled.
Primary packaging material:In certain embodiments of the present disclosure, the term "primary packaging material" may refer to those containers that are in direct contact with the drug product, e.g. with the radioactive solution. Such primary packaging material may be a glass vial with a rubber stopper and a cap; or a glass vial with an all-plastic push-fit cap, wherein the rubber stopper is pre- assembled in the cap, for example, a RayDyLyo cap by Araymond;or a cartridge, e.g. a glass cylinder that is closed by rubber pieces, wherein at least one rubber piece is movable, said cartridge may be then used by loading into syringe devices; or a prefilled syringe. Such primary packaging material may be provided in tubs that are sealed, e.g. by foils, such as those commercialized under the name Tyvek by DuPont (e.g. made out of high-density polyethylene - 15-PATO59492 FF (HOPE)). Such sealed tubs containing the primary packaging material may be then wrapped in a further bag.
Inspecting (Step 4):In certain embodiments of the present disclosure, the term "inspecting" may refer to steps that control the quality and integrity of the drug product. Those inspecting or inspection steps may be in-process controls or final product controls. Those inspection steps may be container closure integrity tests (CCIT), radioactive dose measurement/calibration, visual inspection, head space analysis, or any other product quality controls.
Cleanliness zoning requirements:Clean room and clean air devices are classified in accordance with EN ISO 14644-1. The maximum permitted airborne particle concentration for each grade is given in the following table.
The approximate airborne particle classification per ISO 14644-1 standards is listed in the table Maximum permitted number of particles per m3 equal to or greater than the tabulated size At Rest In Operation Grade 0.5 pm 5.0 pm 0.5 pm 5.0 pm A 3 520 20 3 520 20B 3 520 29 352 000 2 900 C 352 000 2 900 3 520 000 29 000D 3 520 000 29 000 Not Defined Not Defined below. Approximate airborne particle classification per ISO 14644-1 standards At Rest In Operation Grade 0.5 pm 5.0 pm 0.5 pm 5.0 pm A ISO 5 ISO 5 ISO 5 ISO 5B ISO 5 ISO 5 ISO? ISO? C ISO? ISO? ISOS ISOSD ISOS ISOS Not Defined Not Defined The Grade "Controlled, Non-Classified" (CNC) refers to a cGMP manufacturing area designed to produce a consistent and controlled environment, but not necessarily monitored to a given environmental classification. Non-classified areas may have uncontrolled airborne particle amounts, but temperature and humidity are still maintained. Non-classified area may be a non- process area or area in which the product does not comes in direct contact with air. - 16-PATO59492 FF REFERENCES AH publications, patents and patent applications referred to herein are incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.
EXAMPLES Hereinafter, the present invention is described in more details and specifically with reference to the examples, which however are not intended to limit the present invention.
Example 1: General information, preparations The production of radiopharmaceuticals occurs in the synthesis modules and is carried out every time with a new cassette, new set of reagents and new tubing. All consumables are sterile and single use.
All the transfer lines of the solution are sterile and single use. In every step of the production and distribution processes, the starting materials, the intermediate and final products are in contact with sterile, single-use material.
The manufacturing isolator is decontaminated prior to each manufactured batch using qualified vaporized hydrogen peroxide cycles. The isolator cannot be cleaned immediately after production due to the high exposure of radioactivity and should be done when radioactivity levels have dropped or when all items have been consolidated and can be removed in a way that promotes ALARA practices.
The cleaning of the hot cells is therefore carried out before each daily production cycle. The clean room is cleaned every day after the production according to the procedure. - 17-PATO59492 FF The sterile radiopharmaceuticals for injection are produced by utilizing automated synthesis module and diluted under aseptic conditions and using aseptic techniques. The radionuclide used is supplied by IDB, MURR, or ITM.
The synthesis is performed using a radiosynthesis module. This module is contained within a shielded hot cell and utilizes a 0.2 um filtration as the drug substance is transferred into the hot cell. The module is automated and controlled by a software which includes the check and registration of parameters of the method. The software also records the conditions under which manufacturing occurs and reports these conditions.
The aqueous solution containing 177LuCla is transferred into the radio synthesis module by capillary tubes into a reactor vessel. The Reaction Buffer and ligand peptide are transferred into the same reactor vessel. The solution goes through the radio-labelling step for about five minutes prior to being transferred to the dispensing hot cell.The drug substance is filtered through a 0.2 um filter and is transferred into a sterile mother vial. The drug substance is then diluted to the drug product and dispensed through sterilizing filter into a sterile container.
Packaging and Labeling The packaging of radiopharmaceuticals requires specific measures of radioprotection. The packaging is essentially composed of three parts: the glass vial (primary packaging), the lead container (sub-secondary packaging) and type A container (secondary packaging).
The packaging system follows ADR regulations relating to the transport of hazardous goods by road and is temperature controlled using gel packs to ensure the stability of the product.
The labelling is done on primary packaging, sub-secondary packaging and secondary packaging.
Storage of Finished Products Because of the short shelf life (72 hours to 120 hours), radiopharmaceuticals are shipped to hospitals after lot release by Quality. In general, doses are produced on day one, released by - 18-PATO59492 FF Quality and shipped to hospitals on day two, to then be administrated to patients on day two or three following manufacturing completion.
Automated process line Schematic overview of modules within new filling line is provided by Figure 1 for an overview and Figure 2 and Figure 3 for the details.
The units of the process line are described in the following.
Grade C unit (Synthesis) Description of activity:- Activity is measured upfrontMaterials added via open door (including transfer and connection of radio-isotope) SynthesisOptional: automatic system to install all needles into reagent containers-including radio- isotope- Transfer of product via disposable tubing to compounding cell (note: tube installed prior to startup of the campaign)- Transfer of waste to waste box 1EM sampling (start)Equipment:Isolatortype box grade C/shieldedOptional: Tool to install/verify reagentN2 for transfers- Transfer system to compounding- Transfer system to waste box1Gloves in plexipanel & access ports in shielded door- 2 (double) synthesis units (Trasis) & disposables are installed by operatorCritical aspects:Grade C conditions at rest and during operationsIQ/OQ provided by the equipment supplierQualification of the grade with running equipment, synthesis equipment and process (PQ) is done by done by operator - 19-PATO59492 FF Waste box Description of activity:Collection of waste from synthesis boxes and filling unit respectively- Transfer mechanism and lay-out to be defined by the supplierProposal for maximal compression of waste volume to be made by the supplier Equipment:If applicable: equipment to reduce volume of wasteBoxes can be in non-classified environment (shielded)Gloves in plexipanel & access ports in shielded doorCritical aspects:Non GMP critical activity Grade C compounding Description of activity:Materials are added via open door. Including sterile, preassembled disposables- Area is used for dose calibration of radioisotope for synthesis or concentrated mother solutionProduct specific: optionally flush closed system with N2 at all relevant steps- Able to manage following sequence:1. Addition & mixing of compounding buffer to saline*2. Labelled product from synthesis cell is transferred in via disposable tubing.3. Dose measurement of the mother solution (250 ml)4. Addition of mother solution to buffer solution5. Adjustment & mixing to final concentrationBackup scenario needs to be developed in case (one) of the synthesis fails (software can can compensatie for dilution factor in case of partial reject)Batch size from 0,5 to 5 liter solution.Finished product is transferred via disposable tubing1. Note: the solution remains in the compounding unit during filling.2. Note: several tubes installed prior to startup of the campaign)EM sampling (at start) -20-PATO59492 FF * This activity must be done separated in time or space:Or the buffer is prepared, mixed, flushed with nitrogen outside the shielded unitsOr the buffer is prepared, mixed, flushed with nitrogen outside in the shielded units before any radioactive material is added.Note: the first solution requires an extra balance, rocking table and pump.
Equipment:Isolatorbox grade C/ShieldedSterility grade disposable filterBalancePeristaltic pump and/or nitrogen for transfersDose calibrator (range: incoming Lu/labelled API)Mixing system to be proposed by supplier (tilting table, recirculation)N2 for flushing of vessels and solutionGloves in plastic panel & telepliersCritical aspects:Grade C conditions at rest and during operationsIQ/OQ provided by the equipment supplierQualified (sterility, leachables, integrity) disposables by equipment supplierProcess qualifeation (PQ grade & process) is done Grade C/B Material entry, VHP Description of activity:Disposable filling materials (provided by machine supplier) and ready to use sterile components (vials, stopper/caps) are added via open door (typically 150 vials per batch)Items are put on shelves/hungBox is closedSecondary packaging is removed via gloves and evacuated- Tubs are placed in transportation unit ("Train")EM sampling (start)- VHP CycleEM sampling (end) -21 -PATO59492 FF Equipment:Isolatorbox grade C before VHP/Grade B after VHPGloves (for removal of primary bag & position into racks)Glove integrity tester- VHP generator & detection systems & safety warning systems (technical area & clean room) for operatorHangers/shelves/transportation systemCritical aspects:Grade C/B conditions at rest and during operationsIQ/OQ provided by the equipment supplierQualified disposables (sterility, leachables, integrity)Cycle development (6 log reduction & aeration < 1 ppm must be completed within about 120 minutes)PQ (grade and VHP cycle) is performed by OPERATOR VHP generators) Description of activity:See relevant sectionsEach generator should be conectable toMaterial entry unit (sanetized at each material enty)Material unpack unit (sanetized per campagn (e.g. daily))Filling line unit (sanetized per campagn (e.g. daily))Equipment:generatorSteris or supplier designCritical aspects:See relevant sections A => Grade A Component Unpack, VHP Description of activity: FASE 1: preparation part A- VHP Cycle of empty box (at start of campaign only)- Transfer of material in from material entry box -22-PATO59492 FF Components: removal of tyvec layer from tubes; removal of packaging materials from stopper/caps and tubing; optional: automated stepPositioning of components for automaticProcessing in filling unitRemove wasteEM sampling (during)Equipment:Isolatorbox grade C before VHP/Grade A after VHP- VHP generator & detection systems & safety warning systems (technical area & clean room) for operator- Transportation systems for componentsGloves in lightly shielded panel with glass leadGlove integrity testerCritical aspects:Grade C conditions before cycle, Grade A condition after cycleIQ/OQ provided by the equipment supplierCycle development should be done by the equipment supplier (6 log reduction & aeration < 1 ppm must be completed within about 120 minutes)PQ (grade, media fill and VHP) is performed by OPERATORDescription of activity: FASE 1: operation part ANo interventions should be needed (except unblock jams): components enter automaticallyEM sampling (during)Equipment:See aboveCritical aspects:See aboveDescription of activity: FASE 1: end of operation part AEnd campaign (cleaning) or go back to "preparation A"Equipment:See aboveCritical aspects:See above B => Grade A Filling, VHP -23-PATO59492 FF Description of activity: FASE 1: preparation part B- VHP Cycle of empty box (at start of campaign only)- Transfer of material in from previous boxInstallation of unpacked disposable components (tubing, needle, ...)Connection of tubings/needle/filter tofeeding line, pump & needle holder- install N2 flushing needleEM sampling (during)Filter integrity testing (at the start;Wetting with product)Note: the remainder of the bulk solutionstays in the compounding unitEquipment:Isolatorbox grade C before VHP/Grade A after VHP- VHP generator & detection systems & safety warning systems (technical area & clean room) for operatorGloves in plexipanel & access ports in shielded door & for interventions telepliers/robotic arm-manipulatorGlove integrity testerCritical aspects:Grade C conditions before cycleGrade A condition after cycleIQ/OQ provided by the equipment supplierCycle development should be done by the equipment supplier (6 log reduction & aeration < 1 ppm must be completed in about 60 to 120 minutes)PQ (grade, filter integrity test parameters, media fill and VHP) is performed by OPERATOR Description of activity: FASE 1: operation part BFilling, stopper/cap of vialReading of 2D code and linkt with filling parametersNo interventions should be needed (except unblock jams)Product specific: flush with N2Optionally fill full area with N2 -24-PATO59492 FF EM sampling (during)Equipment:See above (interventions only with telepliers)Filling & Stoppering/capping unit with integrated balance. Avoidance of post fill dripping is critical.Camera (reading of 2D code)Oxigen detection systems & safety warning system for operatorLAF protecting the exit (mousehole: where needed additional valves/shuts need to be installed)Critical aspects:See abovePQ (see above, filling and closing accuracy) is performed by OPERATORDescription of activity: FASE 1: end of operations part BRun the line emptyReturn to normal air (in case of N2 optional)Disconnect the feeding lineRemove disposable components to the radioactive waste boxEnd campaign (cleaning) orgo back to "preparation B"Filter integrity testingEquipment:Filter integrity testerCritical aspects:See above CCIT inspection, Hold (prelabeled lead pot) for reject Description of activity:- Vials are presented to CCIT testerUnit is transferred from CCIT testerSuspected units are put in a pre-labelled lead pot "suspected CCIT" pending investigation (buffer of 10 vials)Document and return integer vials back to the lineEquipment:CCIT test equipment to be proposed by vendor: -25-PATO59492 FF - VD (vacuum decay) ME (mass extraction)Detection of 10 urn leaksPick and place unit for vial transportCamera (reading of 2D code)(check on uniqueness at least within batch)Gloves in plexipanel & access ports in shielded doorPre-labelled lead potsEnsure stable temperature/avoid condensation after filling stepCritical aspects:Qualification of testing equipmentIQ/OQ must be provide by the equipment supplier PQ (equipment validation) is done by OPERATOR Dose-measurement Description of activity:- Vials are presented to dose-calibratorFeedback is given to the software (see below) and operator if the result is: non-conform with the target (x%) ordeviating from the expectations (bulk measurement & volume) (y%) (parameters x and y can be entered in the software)Unit is transferred (independently of the status)Equipment:Dosecalibrator for finished productNon conform vials are identified for rejectionCamera (reading of 2D code)Gloves in plexipanel & access ports in shielded doorPick and place unit for vial transportCritical aspects:IQ/OQ must be provide by the equipment supplierPV (Qualification of process and testing equipment) is done by OPERATOR Visual inspection (VI) Description of activity: -26-PATO59492 FF - Vials are presented by the machine against black and white backgroundRotation speed and light intensity is adjustableSequence is video-tapedSequence is evaluated on screen by production and AQL by qualityUnit is transferred (independently of the visual inspection status)- Any investigation is performed off lineEquipment:Camera for visual inspectionC amera for reading of 2D codeComputer screens (remote) and pass/fail keys (production operator(s) & quality)Data Storage server & software to present sequence to 1 or 2 operators (based on availability) and AQL sample to a quality operator (see also slide on visual inspection software)Gloves in plexipanel & access ports in shielded doorCritical aspects:Inspection conditionsin line with pharmacopea(light/duration)Software qualificationIQ/OQ must be provided by the equipment supplier PV (process) and operator is done by OPERATOR (Optional) Head Space Analysis Description of activity:- Vials are presented to HSA testerUnit is transferred from HSA testerEquipment:HSA tester (Specifications to be defined)Pick and place unit for vial transportCamera (reading of 2D code)Gloves in plexipanel & access ports in shielded doorCritical aspects:Qualification of testing equipment -27-PATO59492 FF IQ/OQ must be provide by the equipment supplierPQ (equipment validation) is done by OPERATOR Labelling vial & lead pot + seal Description of activity:- Vials are identified by camera for 2D codeNote: the system has to ensure that the correct version of the labels is used (country & revision number)Paper label is printed and attached to the vial (reject vials are labelled as such*)- Vial is put into a lead containerPaper label is printed and attached to the lead container. Container is sealed, (reject lead pots are labelled as such*)OPERATOR will evaluate to stardardize on a fixed window location for lot-variable information and label ID code. However, variability on color preprinted info is huge, probably requirering in line color printing.Note: * vials rejected in visual inspection might need relabeling afterwards Equipment:Camera’sreading of 2D code on vial- version of preprinted info (country & revision = label ID)- verifying lot variable information- Application of sealPicture of vial and lead pot labels as part ofthe batch documentation- 2 label printers & applicatorsGloves in plexipanel & access ports in shielded doorCritical aspects:Qualification of labelling processIQ/OQ must be provide by the equipment supplierPQ is performed by OPERATOR -28-PATO59492 FF Hold (prelabeled lead pot) for reject; Finished product; VI; Reject Description of activity:Lead pots are sorted automatically (fill volume, CCIT, dose, visual inspection, head space (optional) on the release or reject lane.Up to 150 processed lead pots are collected outside the line.In addition, units that failed visual inspection are manually sorted out, scanned and added to the "reject" vial units. They are labeled as rejects and receive an extra label (confirmed by scanning)Equipment:Camera to read the label on lead pot- Transportation beltCritical aspects:Qualification of sorting processIQ/OQ must be provide by the equipment supplierPQ is performed by OPERATOR Temperature, Relative Humidity, Pressure and Particle Count Monitoring SystemThe general environmental monitoring system has been installed and validated to ensure the following conditions are properly monitored:Temperature: 16 to 25°C (61 °F to 77T).Relative humidity: 28 to 70% RH.Cooling capacityDifferential pressureNon-viable particle counts Particle Counters are used for monitoring the Class A distribution and preparation isolators during production.In each pharmaceutical area, the pressure differentials are monitored by Digihelic pressure monitoring device.
Gas supply system: Compressed Air and NitrogenThe compressed air used for inflating production/isolator line gaskets is produced from an Atlas SF8+ and an Atlas SF15+ compressed air generators which collect compressed air -29-PATO59492 FF in a vertical air receiver located in the Air Compressor Room. The compressed air leads to the production lines, the sterility testing laboratories, QC labs, and the Technical Operations Room, passing through PTFE (P)-SRF filters.Nitrogen is supplied to part of the facility from a compressed nitrogen gas cylinder connected to a distribution manifold in the packaging room. The manifold supplies nitrogen to production lines 1-4, and the QC labs, passing through PTFE (P)-SRF filters. The manifold has the capacity to accommodate up to four cylinders regulated by the manifold itself. An additional single cylinder supplies nitrogen to production lines 5-6 and the Technical Operations Room, passing through PTFE (P)-SRF filters. The distribution lines are built of stainless steel and distribute the gases through the opening/closing of valves.

Claims (21)

-30-PATO59492 FF Claims
1. A method for producing a packaged radiopharmaceutical drug product (e.g. a radioliganddrug product) comprising the steps of:(1) Synthesizing and compounding a radiopharmaceutical drug substance solution in one or more shielded units of (cleanliness zoning requirement) Grade C to obtain a radiopharmaceutical drug product;(2) Providing primary packaging materials, e.g. by (outer-layer-)unpacking in one or more cold units of Grade C, sanetizing in one or more cold units of Grade B, and (inner-layer-)unpacking said packaging materials in one or more cold units of Grade A;(3) Filling the radiopharmaceutical drug substance solution obtained by step (1) into the primary packaging materials as provided and unpacked by step (2) in a shielded unit of Grade A to obtain the primarily packaged radiopharmaceutical drug product;(4) Inspecting the primarily packaged radiopharmaceutical drug product obtained by step (3) in one or more shielded units of Grade “Controlled, non-classified” (CNC); and(5) optionally, placing the primarily packaged radiopharmaceutical drug product as inspected by step (4) into a shielded secondary packaging material in one or more shielded units of Grade CNC to obtained a primarily and secondarily packaged radiopharmaceutical drug product.
2. The method for producing a packaged radiopharmaceutical drug product according to claim 1, wherein in step (4) a container closure integrity test (CCIT) of the primarily packaged radiopharmaceutical drug product is performed as one of the first inspecting steps, preferably, the CCIT is performed with the primarily packaged radiopharmaceutical drug product present in a(n additional) container that allows capturing/segregation of the drug product in said container in case of any leakage detection or risk of spillage.
3. The method for producing a packaged radiopharmaceutical drug product according to claim 1 or 2, wherein in step (4) a camera assisted visual inspection (VI) is performed in the form of video recordation, preferably, said video recordation is then evaluated by naked-eye. - 31 -PATO59492 FF
4. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding claims, wherein in step (1) the synthesizing step is performed several times, preferable up to 4 times, preferably said synthesizing step is performed in parallel in several synthesizing units, and the resulting synthesized radiopharmaceutical drug substance solutions are then collected as one combined (bulk) volume for compounding.
5. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding claims, wherein in step (1) the synthesizing step is performed in a cassette-based synthesis units, preferably said cassette-system manufacturing synthesizer unit as provided e.g. by Trasis, preferably MiniAIO as described e.g. in WO 2020/089379 A1, preferably, two double synthesis units by Trasis are used.
6. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding claims, wherein in step (1) the compounding step comprises the sub-steps of:(i) Filling the synthesized solution(s) into a container, e.g. a (bulk) vial or bottle to obtain a (concentrated) mother solution;(ii) optionally, measuring the radioactivity of said (concentrated) mother solution;(iii) optionally, transferring said (concentrated) mother solution into another contrainer, preferably a flexible plastic bag,(iv) adding a dilution solution in an amount to obtain the drug substance solution in the desired radioactive concentration; and(v) mixing the solution as result of step (iv), preferably and if applicable, by moving the flexible plastic bag appropriately, to obtain a homogeneous diluted drug substance solution for filling.
7. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding claims, wherein in step (2) the packaged primary packaging material is (bio)decontaminated/sanitized, preferably with vaporized hydrogen peroxide (VHP), before being transferred from the unit of Grade B to the unit of Grade A.
8. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding claims, wherein in step (4) inspecting comprises the following sub- steps: - 32 -PATO59492 FF (i) CCIT;(ii) radioactive dose measurement/calibration;(iii) visual inspection; and(iv) optionally, head space analysis; preferably in said order.
9. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding claims, wherein the primary packaging material comprises a glass vial and an all-plastic push-fit cap, wherein the rubber stopper is pre-assembled in the cap, for example, a RayDyLyo cap by ARaymond.
10. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding claims, wherein the shielded secondary packaging material comprises a lead pot with a corresponding lid, preferably with a tamper evident application, preferably said lead pot and its lid is free of a paint-coating, preferably said lead pot and its lid are plastic-coated, preferably a rubber ring is present between pot and lid for leakage-safe closure.
11. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding claims, wherein the drug substance carrying containers and tubings connecting said containers are flushed with protective gas / inert gas, for example nitrogen (N2) and/or argon (Ar).
12. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding claims, wherein the solutions involved in the method are transferred from one container to the other via tubings by applying overpressure of protective gas / inert gas, for example nitrogen (N2) and/or argon (Ar), preferably, said transfer is preceded by testing the tubings for flow and leakage, e.g. by a pressure test with said protective gas / inert gas.
13. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding claims, wherein the solutions used in the method are purged and/or flushed with protective gas / inert gas, for example nitrogen (N2) and/or argon (Ar). -33-PATO59492 FF
14. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding claims, wherein the at least the steps (1) - (3) are automated, preferably also the steps (4) and (5) are automated, with the exception of the naked-eye evaluation of the video recordation in step (4).
15. The method for producing a packaged radiopharmaceutical drug product according any one of the preceding claims, wherein said product is produced on a scale of at least Ci, preferably at least 32 Ci, more preferably 35 Ci, even more preferably at least 40 Ci.
16. A packaged radiopharmaceutical drug product obtained (and/or obtainable) by the methods as described in anyone of the preceding claims.
17. A manufacturing unit (e.g. in the form of a(n automated) process line) comprising the technical equipment and facilities for produdig a packaged radiopharmaceutical drug product according to the methods as described in anyone of the preceding claims.
18. Use of the manufacturing unit according to claim 17 for producing the packaged radiopharmaceutical drug product.
19. A method of treating a cancer comprising administering to a patient in need thereof a therapeutically effective amount of the radiopharmaceutical drug product contained in the packaged radiopharmaceutical drug product according to claim 16.
20. The radiopharmaceutical drug product contained in the packaged radiopharmaceutical drug product according to claim 16 for use in the treatment of a cancer.
21. Use of the radiopharmaceutical drug product contained in the packaged radiopharmaceutical drug product according to claim 16 for the preparation of a medicament for the treatment of a cancer.
IL324086A 2023-05-09 2025-10-20 Production method IL324086A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363500937P 2023-05-09 2023-05-09
PCT/IB2024/054472 WO2024231848A1 (en) 2023-05-09 2024-05-08 Method of production

Publications (1)

Publication Number Publication Date
IL324086A true IL324086A (en) 2025-12-01

Family

ID=91586071

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324086A IL324086A (en) 2023-05-09 2025-10-20 Production method

Country Status (7)

Country Link
EP (1) EP4709642A1 (en)
JP (1) JP2026516077A (en)
KR (1) KR20260009321A (en)
CN (1) CN121079248A (en)
IL (1) IL324086A (en)
TW (1) TW202444435A (en)
WO (1) WO2024231848A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112969675B (en) 2018-10-31 2024-12-20 意大利国际先进加速器应用有限公司 Method for synthesizing radionuclide complexes

Also Published As

Publication number Publication date
TW202444435A (en) 2024-11-16
KR20260009321A (en) 2026-01-19
CN121079248A (en) 2025-12-05
JP2026516077A (en) 2026-05-19
WO2024231848A1 (en) 2024-11-14
EP4709642A1 (en) 2026-03-18

Similar Documents

Publication Publication Date Title
US20140050635A1 (en) Automatic device for the synthesis of peptide-based radioactive drugs for diagnostic and/or therapeutic use
US10625951B2 (en) Conveyance system for operation in radioactive environment
EP4472678A1 (en) Methods for large scale synthesis of radionuclide complexes
US20260053962A1 (en) Radiopharmaceuticals at Different Activity Reference Times
CA3021874C (en) Systems and methods for sterility testing of radionuclide generator column assemblies
EP4709642A1 (en) Method of production
Sammartano et al. Validation of quality control parameters of cassette-based gallium-68-DOTA-Tyr3-octreotate synthesis
TWI885971B (en) Automatic nuclear medicine dispensing system
US20180209921A1 (en) Systems and methods for assaying an eluate of a radionuclide generator
De Decker et al. The good laboratory practice and good clinical practice requirements for the production of radiopharmaceuticals in clinical research
TW202144018A (en) Kits and methods for preparing radiopharmaceuticals
Hojelse et al. Factors which affect the integrity of radiopharmaceuticals
QUINN III Role of the hospital radiopharmacy
Vacca et al. Quality control of radioactive products for patient administration at the national institutes of health
Dansereau et al. Dose variance associated with calibration and administration of radiopharmaceuticals
Bremer Pharmaceutical Form—Packaging
CA3049013A1 (en) Systems and methods for assaying an eluate of a radionuclide generator
KITS TECHNETIUM-99m RADIOPHARMACEUTICALS: MANUFACTURE OF KITS
CN121152611A (en) Tilting station for transferring fluids
Mani Radiopharmacy practices
Baranowska-Kortylewicz Radioactive drugs in drug development research: quality assurance issues
Boschi et al. Radiopharmacy/Radiochemistry for Conventional Single-Photon Emitting and Therapeutic Radiopharmaceuticals
KR20230077672A (en) Method of continuous production of f-18 sodium fluoride
BREMER Institute for Energy Technology, Box 40, N-2007 Kjeller, Norway.
Bremer The Principles and Practice of Radiopharmaceutical Production